DK1846424T3 - Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf - Google Patents

Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1846424T3
DK1846424T3 DK06734698.1T DK06734698T DK1846424T3 DK 1846424 T3 DK1846424 T3 DK 1846424T3 DK 06734698 T DK06734698 T DK 06734698T DK 1846424 T3 DK1846424 T3 DK 1846424T3
Authority
DK
Denmark
Prior art keywords
methods
proteasome inhibitors
compositions
proteasome activity
compounds
Prior art date
Application number
DK06734698.1T
Other languages
English (en)
Inventor
Ambrogio Oliva
Raffaella Bernardnini
Arasmo Germano D
Paolo G Cassara
Alberto Bernareggi
Ernesto Menta
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK1846424T3 publication Critical patent/DK1846424T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK06734698.1T 2005-02-11 2006-02-10 Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf DK1846424T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65237005P 2005-02-11 2005-02-11
US11/351,193 US7468383B2 (en) 2005-02-11 2006-02-09 Proteasome inhibitors and methods of using the same
PCT/US2006/004664 WO2006086600A1 (en) 2005-02-11 2006-02-10 Proteasome inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
DK1846424T3 true DK1846424T3 (da) 2010-05-17

Family

ID=36579482

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06734698.1T DK1846424T3 (da) 2005-02-11 2006-02-10 Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf

Country Status (20)

Country Link
US (2) US7468383B2 (da)
EP (1) EP1846424B1 (da)
JP (1) JP2008530108A (da)
AT (1) ATE456571T1 (da)
AU (1) AU2006213814B2 (da)
CA (1) CA2597273C (da)
CY (1) CY1109985T1 (da)
DE (1) DE602006012013D1 (da)
DK (1) DK1846424T3 (da)
ES (1) ES2339698T3 (da)
HK (1) HK1106534A1 (da)
IL (1) IL184678A (da)
MX (1) MX2007009664A (da)
MY (1) MY147921A (da)
NZ (1) NZ560607A (da)
PL (1) PL1846424T3 (da)
PT (1) PT1846424E (da)
SI (1) SI1846424T1 (da)
TW (1) TWI367886B (da)
WO (1) WO2006086600A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
WO2007011760A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
PT1948678E (pt) 2005-11-09 2013-07-16 Onyx Therapeutics Inc Compostos para inibição de enzimas
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
CN105837608B (zh) * 2007-08-06 2018-06-08 米伦纽姆医药公司 蛋白酶体抑制剂及其组合物和用途
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
ES2578905T5 (es) 2007-10-04 2020-03-18 Onyx Therapeutics Inc Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos
EP2212334B1 (en) * 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
GEP201706703B (en) 2008-06-17 2017-07-25 Millennium Pharmaceuticals Inc (A Delaware Corporation) Boronate ester compounds and pharmaceutical compositions thereof
KR20110092266A (ko) * 2008-08-04 2011-08-17 씨에이치디아이 파운데이션, 인코포레이티드 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
CN102725300B (zh) 2009-12-22 2015-03-11 赛福伦公司 蛋白酶体抑制剂及其制备、纯化、和应用的方法
CN102811620B (zh) 2010-01-25 2015-03-25 Chdi基金会股份有限公司 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
MA34133B1 (fr) * 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
EP2627636B1 (en) * 2010-10-14 2015-09-02 Synthon BV Process for making bortezomib and the intermediates for the process
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA027451B1 (ru) 2011-08-30 2017-07-31 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
US9493439B1 (en) 2014-04-07 2016-11-15 University Of Kentucky Research Foundation Proteasome inhibitors
RS57624B1 (sr) * 2014-04-08 2018-11-30 Neurovive Pharmaceutical Ab Nova sukcinatna jedinjenja koja prodiru u ćelije
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
SG11201907945YA (en) * 2017-02-28 2019-09-27 Chia Tai Tianqing Pharmaceutical Group Co Ltd Azetidine derivative
GB201808149D0 (en) 2018-05-18 2018-07-11 Univ Court Univ Of Glasgow Protected amino acids
CN112513052B (zh) * 2018-08-02 2022-12-16 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物的硼酸酯

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301354A1 (de) 1983-01-18 1984-07-19 Matth. Hohner Ag, 7218 Trossingen Elektronisches musikinstrument
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
WO1989009225A1 (en) 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
US5023236A (en) 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
IE910713A1 (en) 1990-03-05 1991-09-11 Cephalon Inc Chymotrypsin-like proteases
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
JPH08507754A (ja) 1993-02-10 1996-08-20 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ Ｍｈｃ−１拘束性抗原提示におけるａｔｐ−ユビキチン依存蛋白分解の役割およびそのインヒビター
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
ES2184763T3 (es) 1993-04-30 2003-04-16 Merck & Co Inc Inhibidores de trombina.
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
FR2707085B1 (fr) 1993-06-30 1995-08-18 Adir Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
KR100316865B1 (ko) 1993-10-01 2002-11-29 메렐 파마슈티칼스 인크. 베타-아밀로이드단백질생성억제제
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
UA66767C2 (uk) 1996-10-18 2004-06-15 Вертекс Фармасьютикалс Інкорпорейтед Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
EP1037626A1 (en) 1997-12-16 2000-09-27 Cephalon, Inc. Multicatalytic protease inhibitors for use as anti-tumor agents
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
BR9914648A (pt) 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
EP1053750A1 (en) 1999-04-22 2000-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
AU4555800A (en) 1999-04-27 2000-11-10 Novartis Ag Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
SE9901573D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
AU7832000A (en) 1999-09-23 2001-04-24 Washington University Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof
JP2003528039A (ja) 1999-10-20 2003-09-24 オステオスクリーン，インコーポレイテッド 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
EP1303487A4 (en) 2000-07-21 2005-11-23 Schering Corp NOVEL PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
CA2425632A1 (en) 2000-10-12 2002-04-18 Viromics Gmbh Agents for the treatment of viral infections
EP1355910B1 (en) 2001-01-25 2011-03-09 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
CN1531653A (zh) 2001-04-09 2004-09-22 ����������˹�ٰ���Ф 用于鉴定胞内细菌蛋白质的方法
WO2002094857A1 (en) 2001-05-23 2002-11-28 The Curators Of The University Of Missouri Inverse solid phase synthesis of peptides
US6933290B2 (en) 2001-05-30 2005-08-23 Novartis Ag 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives
KR100399359B1 (ko) * 2001-07-07 2003-09-26 삼성전자주식회사 전하 펌프 회로
AU2002324734A1 (en) 2001-08-16 2003-03-03 Levente Fabry-Asztalos Borinic acid protease inhibitors
WO2003033507A1 (fr) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
JP4412586B2 (ja) * 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
US20060237868A1 (en) 2003-08-13 2006-10-26 Seiko Precision Inc. Method and device for manufacturing card
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
PL2178888T3 (pl) 2007-08-06 2012-11-30 Millennium Pharm Inc Inhibitory proteasomów

Also Published As

Publication number Publication date
ES2339698T3 (es) 2010-05-24
US20090075936A1 (en) 2009-03-19
MX2007009664A (es) 2007-09-26
AU2006213814B2 (en) 2011-10-13
AU2006213814A1 (en) 2006-08-17
JP2008530108A (ja) 2008-08-07
IL184678A (en) 2012-05-31
SI1846424T1 (sl) 2010-05-31
CA2597273A1 (en) 2006-08-17
WO2006086600A1 (en) 2006-08-17
ATE456571T1 (de) 2010-02-15
TW200640936A (en) 2006-12-01
NZ560607A (en) 2009-11-27
US20060189806A1 (en) 2006-08-24
PL1846424T3 (pl) 2010-06-30
IL184678A0 (en) 2007-12-03
EP1846424B1 (en) 2010-01-27
MY147921A (en) 2013-02-15
TWI367886B (en) 2012-07-11
EP1846424A1 (en) 2007-10-24
CY1109985T1 (el) 2014-09-10
US7468383B2 (en) 2008-12-23
DE602006012013D1 (de) 2010-03-18
PT1846424E (pt) 2010-04-15
HK1106534A1 (en) 2008-03-14
CA2597273C (en) 2013-12-17
US8283367B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
HK1089153A1 (en) Proteasome inhibitors and methods of using the same
PH12015501868A1 (en) Inhibitors of histone demethylases
PH12014500053A1 (en) Proteasome inhibitors
ATE486870T1 (de) Jnk inhibitoren
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MY162518A (en) Proteasome inhibitors and methods of using the same
MY180594A (en) Proteasome inhibitors
EA201791835A2 (ru) Ингибиторы протеасом